喹硫平与利培酮治疗精神分裂症的对比分析  

The Comparison and Analysis of the Schizophrenia Treatment with Quetiapine and Risperidone

作　　者：高海江[1] 高海英[1] 张淑艳[1] 窦建军[1] 刘炳书 苟汝红 张继青[1] 强瑞香 

机构地区：[1]秦皇岛市九龙山医院,河北秦皇岛066601

出　　处：《医学与哲学（B）》2011年第5期44-45,共2页Medicine & Philosophy(B)

摘　　要：探讨喹硫平治疗精神分裂症的临床效果及安全性。将210例精神分裂症患者随机分为两组,分别给予喹硫平与利培酮治疗8周。采用阳性与阴性症状量表(PANSS)、不良反应量表(TESS)评定疗效及不良反应。喹硫平组治疗总有效率为82.08%,利培酮组为82.69%,两组比较差异无统计学意义(P>0.05)。但喹硫平组的不良反应稍低于利培酮组(P<0.05)。喹硫平与利培酮治疗首发精神分裂症的疗效相当,且喹硫平不良反应少。To explore the clinical effect and safety of schizophrenia treatment with Quetiapine, 210 Schizophrenia patients were randomly divided into two groups and they were separately given Quetiapine and Risperidone for treatment for 8 weeks. The positive and negative symptoms scales （PANSS） and the adverse reactions scale （TESS） were used to assess the efficacy and the adverse reactions. The total effectiveness of treatment group with Quetiapine was 82.08%, and the Risperidone treatment group was 82.69%, the difference of the two groups was statistically significant （P〉0.05）. However, the adverse reactions of the Quetiapine group are slightly lower than the Risperidone group （ P〈0.05 ）. The clinical effect of starting treatment of schizophrenia with Quetiapine and Risperidone is equal, and the treatment with Quetiapine has less adverse reactions.

关 键 词：精神分裂症 治疗 喹硫平 利培酮 

分 类 号：R971.41[医药卫生—药品]